MARKET NEWS

Downstream Demand of LAD Industry is Stable

A left ventricular assist device (LVAD) is a pump used for patients who have reached end-stage heart failure. Doctors surgically implant the LVAD, a battery-operated, mechanical pump, which then helps the left ventricle (main pumping chamber of the heart) pump blood to the rest of the body. LVADs can be used as Bridge-to-transplant therapy and Destination therapy.

Bridge-to-transplant therapy: This is a life-saving therapy for patients awaiting a heart transplant. Patients use the LVAD until a heart becomes available. In some cases, the LVAD is able to restore the failing heart, eliminating the need for a transplant. BTD (bridge to decision) is, in a broad sense, a case of severe heart failure with cardiogenic shock, and refers to wearing an extracorporeal LVAD as a life-saving measure until an indication for heart transplantation can be made. However, in a narrow sense, it often refers to wearing in cases where the indication for extracorporeal LVAD is unknown. Destination therapy: Some patients are not candidates for heart transplants. In this case, patients can receive long-term treatment using an LVAD, which can prolong and improve patients\' lives.

A left ventricular assist device (LVAD) can save the life of a patient with heart failure. These mechanical pumps, implanted in the chest cavity, deliver oxygen-rich blood to various parts of the body when needed to help the patient\'s heart function properly. For the downstream market, implantation is a necessity if needed, so the impact on downstream demand is not significant.

Get the Complete Sample, Please Click: https://www.globalmarketmonitor.com/reports/879410-lvad-market-report.html

The increasing burden of heart disease and heart failure is a major force driving the LVAD market globally

Heart failure and stroke is one of the key factors driving the growth of the market. Although heart transplantation (HTx) is the best surgical treatment for end-stage heart failure (HF), this treatment option is becoming increasingly limited. The gap between donor and recipient is widening due to lack of suitable heart donors. LVAD implants are life-saving devices for patients with severe heart failure. They help minimize the symptoms of heart failure, thereby helping patients return to daily activities. Coronary heart disease associated with high blood pressure is a very common cause of chronic heart failure. In addition to this, other heart conditions such as ischemic and dilated cardiomyopathy require significant surgical intervention. Heart transplantation is a long-term successful procedure for all patients who require advanced heart failure-related treatment. However, the waiting time is generally long because of the low supply of organs. Such cases require immediate assistance from an LVAD, which can serve as a bridge to transplantation. Here, the demand for and availability of LVADs plays a crucial role and hence, the increasing burden of heart disease and heart failure is a major force driving the LVAD market globally.

Left ventricular assist devices (LVADs) are now an important treatment strategy for patients with end-stage heart failure, but LVAD implantation can cause abnormal activation of the coagulation-fibrinolytic system, resulting in severe bleeding and thrombotic events that are the most common complications of treatment: bleeding requiring surgical intervention in up to 30% of adult patients and up to 50% of pediatric patients, as well as adverse events such as stroke due to thrombosis and embolism, which significantly affect the long-term outcome of patients with LVAD implantation.

The threshold for LVAD industry is high, and it is difficult for late entrants to seize the market position

The LVAD industry requires a high level of talent and technology, and the LVAD industry involves multiple disciplines, including biology, materials science, electronics, and computer science, in addition to clinical medicine. In addition to clinical medicine, the LVAD industry involves multiple disciplines, including biology, materials science, electronics, computers, etc. The R&D team of an enterprise needs long-term investment and experience to reach a certain level, and new entrants cannot acquire technology in a short period of time.

Secondly, the formation of a well-known brand requires longterm cooperation and trust between LVAD company and distributors and hospitals, and the quality, stability and design level of the products need to be guaranteed, which requires long-term precipitation in the market. The degree of concentration in LVAD industry is very high, and the brand effect accumulated by leading enterprises plays a role, so it will be difficult for players who enter afterwards to occupy a larger market in the industry.

Abbott (Thoratec), Heart of Berlin, and Medtronic are the top players in this segment and are well established in the developed markets. Moreover, new product launches and continuous support from the government are expected to boost the growth of the segment. For example, in February 2020, Abbott received the Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Fully Implantable Left Ventricular Assist System (FILVAS), which is currently under development. And in 2018, the FDA launched the Breakthrough Device Program to help expedite the development and review of technology submissions that offer significant advantages over approved products. In adults, VADs play a useful role in bridging the transition to heart transplantation, providing recovery time for critically ill patients.

According to our research, the global LVAD market has a total sales value of 713.14 M USD back in 2015, and increased to1140.52 M USD in 2020. We made a series of functional calculation and deduced the past 5 year’s data with scientific model. Finally, we made the prediction that the value of LVAD markets can be 1894.47 M USD by 2025. The CAGR of LVAD is 10.29% from 2019 to 2025. The global LVAD market is expected to witness a mild growth during the forecast period because of the prevalence of diseases and the increase in the number of patients. The other factor that is driving the growth of the LVAD market is related technology innovation.

Get the Complete Sample, Please Click: https://www.globalmarketmonitor.com/reports/879410-lvad-market-report.html